BGI Genomics Co., Ltd. (SZSE: 300676)
Health Care · Biotechnology · CN
CN¥45.86
+1.64% today · -8.6% 1Y
BGI Genomics Co., Ltd. (SZSE: 300676) operates in the Biotechnology industry within the Health Care sector. The company is valued at $2.62B and employs 3,580 people.
Over the last twelve months the share price has lost 8.6%, trading between 32.55 and 65.00.
Tweenvest scores BGI Genomics Co., Ltd. across four factors: quality 62/100, value 53/100, growth 0/100. Its strongest factor is quality.
300676 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $2.62B
- Revenue (TTM)
- $568.53M
- P/E
- —
- EPS
- -1.38
- Dividend yield
- —
- Beta (5Y)
- 0.66
- 52-week high
- CN¥65.00
- 52-week low
- CN¥32.55
- Avg volume (3M)
- —
- Shares outstanding
- 383.85M
- Employees
- 3,580
- Next earnings
- —
About BGI Genomics Co., Ltd.
BGI Genomics Co., Ltd. operates as an international supplier of genetic testing solutions and sequencing services. The company caters to a broad clientele, encompassing medical and research facilities, as well as other public and private organizations, both within China and across the globe. Its comprehensive service portfolio includes DNA, RNA, and tailored sequencing options. Additionally, it offers a suite of specialized genetic tests such as non-invasive prenatal testing (NIPT), reproductive health screening, and newborn genetic screening, alongside clinical exome sequencing. BGI Genomics also develops clinical and research-focused solutions for the field of oncology. During the COVID-19 pandemic, the firm provided crucial laboratory solutions for the detection and diagnosis of suspected cases, including SARS-CoV-2 IgM and IgG antibody detection kits, and real-time fluorescent RT-PCR kits. Their expertise spans numerous research domains, including but not limited to agriculture and food science, cancer research, metagenomics, reproductive health, biomarker discovery, and drug development. Established in 1999, the company initially operated under the name Shenzhen BGI Medicine Co., Ltd. before officially changing to BGI Genomics Co., Ltd. in 2015. Its corporate headquarters are located in Shenzhen, China.
- ISIN
- CNE100003449
- Founded
- 1999
- Listed since
- Jul 14, 2017
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| NewAmsterdam Pharma Company N.V.NasdaqGM: NAMS | $2.77B | $21.26 | -8.36% |
| Zai Lab LimitedNasdaqGM: ZLAB | $2.73B | $24.81 | +1.97% |
| Yili Chuanning Biotechnology Co.,Ltd.SZSE: 301301 | $2.73B | CN¥8.19 | +2.12% |
| BioArctic AB (publ)OM: BIOA B | $2.70B | Skr305.20 | -2.55% |
| Sinocelltech Group LimitedSHSE: 688520 | $2.60B | CN¥37.05 | +3.64% |
| Zealand Pharma A/SCPSE: ZEAL | $2.54B | Dkr237.00 | -4.97% |
| Bavarian Nordic A/SCPSE: BAVA | $2.53B | Dkr230.00 | +3.05% |
| Disc Medicine, Inc.NasdaqGM: IRON | $2.48B | $60.77 | -5.80% |
Figures last refreshed Oct 4, 2026.